Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 18/20 | 0.72 |
| ▸ | CCR5 | P51681 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257578 | 0.88 | CCR2 (0.78) | CCR2CCR5KCNH2 | |
| SCHEMBL2744807 | 0.88 | CCR2 (0.71) | CCR2CCR5KCNH2CCR1 | |
| SCHEMBL14849041 | 0.88 | CCR2 (0.71) | CCR2CCR5KCNH2CCR1 | |
| SCHEMBL21422801 | 0.88 | CCR2 (0.57) | CCR2CCR5KCNH2TMEM97SIGMAR1 | |
| SCHEMBL21422769 | 0.88 | CCR2 (0.57) | CCR2CCR5KCNH2TMEM97SIGMAR1 | |
| SCHEMBL16938585 | 0.88 | CCR2 (0.66) | CCR2CCR5KCNH2CCR1TMEM97 | |
| SCHEMBL12180185 | 0.88 | CCR2 (0.71) | CCR2CCR5KCNH2CCR1 | |
| SCHEMBL16257515 | 0.86 | CCR2 (0.79) | CCR2CCR5KCNH2 | |
| SCHEMBL10179415 | 0.86 | CCR2 (0.67) | CCR2CCR5KCNH2 | |
| SCHEMBL10180314 | 0.86 | CCR2 (0.65) | CCR2CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-10-03 | — | — | US | disclosed |
| US-10196402-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CCR2 1/4885CCR5 5/4885KCNH2 4033/4885 |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CCR2 1/4885CCR5 5/4885KCNH2 4033/4885 |
| US-10196402-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CCR2 1/4885CCR5 5/4885KCNH2 4033/4885 |
| US-20170362249-A1 | NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | CCR2 1/4885CCR5 4/4885KCNH2 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.